The risk of posterior reversible encephalopathy syndrome (pres) with tyrosine kinase inhibitors: A disproportionality analysis from VigiBase and AERS databases

被引：0

作者：

Velez-Nandayapa, Luis ^{[1
]}

Das, Anusmita ^{[2
]}

Saxena, Amit ^{[2
]}

Parulekar, Vishaka ^{[3
]}

Chhabra, Naveen ^{[3
]}

Izquierdo, Miguel ^{[4
]}

De Zeeuw, Pierre ^{[5
]}

Schaart, Edwin ^{[6
]}

Eisinger, Johannes ^{[5
]}

机构：

[1] Univ Basel, Basel, Switzerland

[2] Novartis, Safety Signal Detect MQM, Basel, Switzerland

[3] Novartis, Patient Safety Oncol, Hyderabad, India

[4] Novartis, Clin Dev Oncol, Basel, Switzerland

[5] Novartis, Patient Safety Oncol, Basel, Switzerland

[6] Novartis, Basel, Switzerland

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

924

引用

页码：425 / 426

页数：2

共 49 条

[1] The Risk of Posterior Reversible Encephalopathy Syndrome with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases
Velez, L.
Das, A.
Saxena, A.
Parulekar, V.
Chhabra, N.
Izquierdo, M.
Zeeuw, P. D.
Schaart, E.
Eisinger, J.
DRUG SAFETY, 2022, 45 (10) : 1250 - 1251
[2] Risk of posterior reversible encephalopathy syndrome with tyrosine kinase inhibitors: A disproportionality analysis from Vigibase and AERS databases
Velez-Nandayapa, Luis
Sharma, Gopal
Janagyraman, Senthilkumaran
Manley, Paul W.
Aimone, Paola
Nicolaides, Maria
de Zeeuw, Pierre
Michel, Christiane
Eisinger, Johannes
Brueckner, Andreas
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 466 - 467
[3] The Risk of Myasthenia Gravis with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases
Velez, L.
Saxena, A.
Izquierdo, M.
Nicolaides, M.
Zeeuw, P. D.
Rossiter, A.
Eisinger, J.
Michel, C.
DRUG SAFETY, 2022, 45 (10) : 1253 - 1253
[4] Risk of myasthenia gravis with tyrosine kinase inhibitors: A disproportionality analysis from vigibase and AERS databases
Velez-Nandayapa, Luis
Saxena, Amit
Izquierdo, Miguel
Nicolaides, Maria
de Zeeuw, Pierre
Rossiter, Alicia
Eisinger, Johannes
Michel, Christiane
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 36 - 37
[5] Risk of thrombotic microangiopathy with tyrosine kinase inhibitors: A disproportionality analysis from VigiBase and AERS databases
Velez-Nandayapa, Luis
Saxena, Amit
Das, Anusmita
Izquierdo, Miguel
Li, Sai
Manley, Paulw
Nicolaides, Maria
de Zeeuw, Pierre
Rossiter, Alicia
Eisinger, Johannes
Michel, Christiane
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 329 - 330
[6] Oral Presentation: The Risk of Oligospermia with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases
Velez, L.
Das, A.
Parulekar, V.
Chhabra, N.
Izquierdo, M.
Nicolaides, M.
Zeeuw, P. D.
Rossiter, A.
Eisinger, J.
Michel, C.
DRUG SAFETY, 2022, 45 (10) : 1125 - 1125
[7] Risk of oligospermia with tyrosine kiase inhibitors: A disproportionality analysis from VigiBase to AERS databases
Velez-Nandayapa, Luis
Das, Anusmita
Parulekar, Vishaka
Chhabra, Naveen
Izquierdo, Miguel
Nicolaides, Maria
de Zeeuw, Pierre
Rossiter, Alicia
Eisinger, Johannes
Michel, Christiane
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 457 - 457
[8] EARLY RECOGNITION AND MANAGEMENT OF POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES): A NEWLY RECOGNIZED COMPLICATION IN PATIENTS RECEIVING TYROSINE KINASE INHIBITORS (TKIS)
Przybylski, Ashley
Olsen, Mikaela
ONCOLOGY NURSING FORUM, 2014, 41 (02) : E105 - E105
[9] Tyrosine kinase inhibitors-associated posterior reversible encephalopathy syndrome: pharmacovigilance data base review
Philibert, L.
Philibert, C.
Miremont, G.
Lebrun-Vignes, B.
Grandvuillemin, A.
Steve, M.
Lillo-Le Louet, A.
Jean-Pastor, M. J.
Pinzani, V.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 48 - 48
[10] Rehabilitation Outcome of Patients Suffering From Posterior Reversible Encephalopathy Syndrome (PRES)
Meiner, Z.
Ofran, Y.
Moreh, E.
Tsenter, J.
Schwartz, I
JOURNAL OF HEAD TRAUMA REHABILITATION, 2020, 35 (02) : E168 - E168

← 1 2 3 4 5 →